Electronic Journal of IFCC (eJIFCC) is officially indexed by MEDLINE/PUBMED. All issues from 1999 onward are available online and are indexed, searchable, downloadable, and citable from PubMed.
To receive the eJIFCC:
Please Click here and select "Subscribe" among the options, thank you
eJIFCC Volume 33 no 2 - 2022
|In this issue: Current laboratory aspects of COVID-19|
|Click here to download a PDF of the full issue.|
|1||Foreword: Current laboratory aspects of COVID-19|
Guest editor: Béla Nagy Jr.
|2||Call for manuscript submissions for a thematic eJIFCC issue on “Pharmacogenetics and Personalized Therapy”|
Ron H. N. van Schaik, Sanja Stankovic
|3||Laboratory considerations for reporting cycle threshold value in COVID-19|
Rivak Punchoo, Sachin Bhoora, Avania Bangalee
|4||Systematic review of diagnostic accuracy of DiaSorin Liaison SARS-CoV-2 antigen immunoassay|
Giuseppe Lippi, Brandon M. Henry, Mario Plebani, Khosrow Adeli
|5||Laboratory features of hospitalised patients with COVID-19 in Jersey, UK|
Sergio Gama, Julie Bellamy, Nadia Couvert, Effie Liakopoulou
|6||Prognostic value of routine blood parameters in intensive care unit COVID-19 patients|
Nada Yousfi, Ines Fathallah, Amal Attoini, Meriem Jones, Mariem Henchir, Zeineb Ben Hassine, Nadia Kouraichi, Naouel Ben Salah
|7||Utility of biochemical markers in predicting severe COVID-19: experience from a tertiary hospital in South India|
Mamatha T. Shenoy, Pradipta Kumar Mohanty, K. Suganthy, Jeya Kumar Manavalan, Hariharan Alexander
|8||Verification and comparison of qualitative serological assays for Anti-SARS-COV-2 IgM and IgG antibodies detection|
Maša Štebih, Milan Skitek, Aleš Jerin
|9||Elecsys and VIDAS Anti-SARS COV-2 for nucleocapsid and spike protein antibody detection|
Riberi María Inés, Hernandez Toledo Marina Gabriela, Cid Mariana Paula, Tenaglia María Magdalena, Alfaro Jimena, Konigheim Brenda Salome, Aguilar Juan Javier, Blanco Sebastián, Spinsanti Lorena, Díaz Luis Adrián, Rivarola Elisa, Beranek Mauricio, Bottiglieri Marina Tersita, Gallego Sandra Verónica, Isa María Beatriz
|10||Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster|
Gian Luca Salvagno, Brandon M. Henry, Laura Pighi, Simone De Nitto, Giuseppe Lippi
|11||Kinetics of antibody response to repeated vaccination with Sputnik V: a pilot study with a series of five cases|
Aleksandra Atanasova Boshku, Vasko Aleksovski, Gligor Tofoski, Rosa Spasova
|12||Newly diagnosed chronic lymphocytic leukemia during symptomatic COVID-19: two cases|
Enikő Papp, Szabolcs Tasnády, Katalin Tisza, Ágnes Király, Gabriella Bekő
|13||Impact of COVID-19 on pediatric laboratory medicine: an IFCC C-ETPLM, SSIEM, ISNS global survey|
Tze Ping Loh, Ronda F. Greaves, Chloe M. Mak, Gajja S. Salomons, James R. Bonham, Tim Lang
Faculty of Medicine
University of Debrecen
|Harjit Pal Bhattoa|
Department of Laboratory Medicine University of Debrecen
Khosrow Adeli, The Hospital for Sick Children, University of Toronto, Canada
Edgard Delvin, CHU Sainte-Justine Research Center, Montréal, Québec, Canada
Nilda E. Fink, Universidad Nacional de La Plata, Argentina
Ronda Greaves, Biochemical Genetics, Victorian Clinical Genetics Services, Victoria, Australia
Mike Hallworth, Shrewsbury, United Kingdom
Andrea R. Horvath, Prince of Wales Hospital and School of Medical Sciences, University of New South Wales, Sydney, Australia
Ellis Jacobs, EJ Clinical Consulting, LLC, USA
Allan S. Jaffe, Mayo Clinic, Rochester, USA
Bruce Jordan, Roche Diagnostics, Rotkreuz, Switzerland
Evelyn Koay, National University, Singapore
Tamas Kőszegi, University of Pécs, Pécs, Hungary
Gábor L. Kovács, University of Pécs, Pécs, Hungary
Gabriel Lima-Oliveira, University of Verona, Italy
Janja Marc, University of Ljubljana, Ljubljana, Slovenia
Gary L. Myers, Joint Committee for Traceability in Laboratory Medicine, USA
Tomris Ozben, Akdeniz University, Antalya, Turkey
Maria D. Pasic, Laboratory Medicine and Pathobiology, University of Toronto, Canada
Maria del C. Pasquel Carrera, College of Chemists, Biochemists and Pharmacists, Pichincha, Ecuador
Oliver Racz, University of Kosice, Slovakia
Rosa Sierra Amor, Laboratorio Laquims, Veracruz, Mexico
Sanja Stankovic, Institute of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia
Danyal Syed, Ryancenter, New York, USA
Grazyna Sypniewska, Collegium Medicum, NC University, Bydgoszcz, Poland
Peter Vervaart, LabMed Consulting, Australia
Stacy E. Walz, Arkansas State University, USA
IFCC Communications and Publications Division (IFCC-CPD)
Copyright © 2000-2022 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.
This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The electronic Journal of the IFCC (eJIFCC) is a platinum open-access journal, i.e. there is no charge to read, or to submit to this journal. Our numerous high-quality articles, debates, reviews, case studies and editorials are addressed to clinical laboratorians. The journal also publishes general news articles, IFCC publicity/news, educational materials and has a letters section. Besides offering original scientific thought in our featured columns, we provide pointers to quality resources on the world wide web. We aim to assist the development of the field of clinical chemistry and laboratory medicine worldwide.
Manuscripts are fully peer reviewed and immediately free to access and download from www.ifcc.org.
The eJIFCC is a member of the Committee on Publications Ethics (COPE).
eJIFCC is archived by PubMedCentral (http://www.ncbi.nlm.nih.gov).
eJIFCC is included in Scopus.
Manuscript preparation: Microsoft Word is preferred, with the use of 12-point font, 2cm margins and double spacing. The title page should list title, authors (first name, last name and initials), each author's affiliation during the study, including e-mail adresses, corresponding author's contact information, key words. All manuscript should be provided with structured Abstracts not longer than 250 words. This information should proceed the text of each submission. Tables should be created in a common word-processing or spreadsheet format and included within the text of the manuscript, close to the first location where they are referenced. The figures must be submitted as independent images or files, with high enough resolution for publishing and printing. All tables and figures must include a short title, with any further explanatory text to be included at the bottom of either. The maximum number of references for a review article is 75, and 40 for original papers. In-text reference numbers should be included paranthetically before punctuation. The actual references shall be presented and punctuated consistently and are to be listed sequentially following the main text, with their numbers unlinked. Manuscripts should provide any required Author's Disclosures. All studies involving human subjects must indicate that they are in compliance with the ethical principles for medical research involving human subjects, in accordance with the Declaration of Helsinki.
The eJIFCC welcomes case reports that illustrate new approaches to established clinical - diagnostic problems or describing a new clinically associated diagnostic problem. To be of value appropriate for publication, a case report must provide a significant learning point for other laboratory physicians and clinical chemists. Case reports should be provided with a summary not longer than 150 words, followed by a structured main text (INTRODUCTION, CLINICAL-DIAGNOSTIC CASE, DISCUSSION, TAKE HOME MESSAGES/LEARNING POINTS) not exeeding 1500 words. Case reports will also allow 2 tables and 2 figures, the maximum number of references is 15, 3-5 keywords are mandatory. Please provide disclosures & contribution of authors at the end of manuscript text.
Submission of manuscripts: Manuscripts should be submitted to the editor-in-chief, via e-mail to: firstname.lastname@example.org.